Ipamorelin + CJC-1295 Stack: The Complete Guide

Why Ipamorelin + CJC-1295 Has Become the Leading Peptide Stack

Among all peptide combinations explored in clinical and research settings, the Ipamorelin + CJC-1295 stack stands out for one key reason: it produces a sustained, physiologically appropriate increase in growth hormone (GH) secretion through two complementary mechanisms. Unlike synthetic HGH — which floods the body with a non-pulsatile hormone surge — this combination stimulates the body's own pituitary to release GH in a pattern that more closely mimics natural secretion.

Understanding Each Peptide

Ipamorelin

Ipamorelin is a selective GHSR (ghrelin receptor) agonist that triggers GH release from the pituitary. It distinguishes itself from earlier growth hormone releasing peptides by:

• Stimulating GH without significantly elevating cortisol or prolactin
• Producing a sharp, clean GH pulse — peaking 30–60 minutes after injection and returning to baseline within 2 hours
• Minimal appetite stimulation compared to ghrelin and GHRP-6
• Not blunting the natural GH axis as dramatically as synthetic HGH

CJC-1295

CJC-1295 is a GHRH analog — it mimics the body's own growth hormone releasing hormone and binds to GHRH receptors on the pituitary. Two versions exist:

• Without DAC (most common in this stack): Shorter half-life (~30 min), producing an acute GH pulse that pairs well with Ipamorelin.
• With DAC: Extended half-life (up to 8 days) via albumin-binding, providing sustained baseline GH elevation.

Why Stack Them Together?

GH release is regulated by two competing signals: GHRH (stimulates release) and somatostatin (inhibits release). CJC-1295 amplifies the GHRH signal. Ipamorelin activates GHSR and suppresses somatostatin. Together, they produce a GH pulse substantially larger than either peptide alone — research suggests 5–10x greater GH release versus individual use. The result closely resembles the body's natural nocturnal GH surge when tissue repair and anabolic signaling are at their peak.

Potential Benefits of the Stack

• Lean muscle development — GH and IGF-1 are potent stimulators of protein synthesis and muscle fiber growth.
• Fat metabolism — GH promotes lipolysis, particularly visceral and subcutaneous fat.
• Recovery — Supports connective tissue repair, collagen synthesis, and cellular regeneration.
• Sleep quality — Administered before bed to amplify the natural nocturnal GH pulse; many users report improved sleep depth.
• Skin and connective tissue — GH and IGF-1 support collagen production affecting skin elasticity and joint health.
• Bone density — GH receptor activity supports osteoblast function and bone mineral density.
• Energy and cognitive function — Optimized GH/IGF-1 levels are associated with improved energy, mood, and cognitive performance.

Typical Dosing Protocols

• Ipamorelin: 100–300 mcg per injection
• CJC-1295 (without DAC): 100–300 mcg per injection
• Frequency: 1–3 times daily; most commonly once before bed, sometimes a second dose post-workout on an empty stomach
• Route: Subcutaneous injection, small insulin-type needle
• Cycling: Some protocols use 5 days on / 2 days off, or 3 months on / 1 month off

Important: Inject in a fasted state (at least 2 hours post-meal). Carbohydrates and fat significantly blunt GH release and reduce peptide efficacy.

What Results to Expect and When

• Weeks 1–4: Improved sleep quality is often the first noticeable effect, with subtle recovery improvements.
• Weeks 4–8: Noticeable changes in muscle fullness and body fat, especially with resistance training and adequate protein.
• Weeks 8–16: More significant body composition shifts, improved skin quality, and joint health improvements.
• Months 3–6+: Maximum body composition and anti-aging effects with sustained consistent use.

Safety Profile and Monitoring

Ipamorelin and CJC-1295 have a favorable safety profile compared to synthetic HGH since they work through natural regulatory mechanisms. Potential side effects include transient water retention, tingling, mild injection site reactions, and increased hunger. Monitoring IGF-1 levels is recommended — elevated IGF-1 beyond the upper normal range signals excess GH activity. Explore our peptide therapy programs for provider-supervised protocols. Also see our guide on peptides for fat loss for complementary options.

Who May Benefit Most

• Adults with documented adult growth hormone deficiency
• Men and women over 35 experiencing declining energy, recovery, and body composition
• Athletes seeking enhanced recovery and lean body mass support
• Those with poor sleep quality (particularly non-restorative sleep)
• Adults with connective tissue issues or chronic injury recovery challenges

A licensed provider should evaluate your hormonal baseline before initiating peptide therapy. Contraindications include active cancer, uncontrolled diabetes, and other specific conditions.